You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

Displaying 1 - 10 of 4511 results
  1. Development and Commercialization of a Tau Oligomer Inhibitor for AD/RD

    SBC: Oligomerix, Inc.            Topic: NIA

    TITLE: Development and Commercialization of a Tau Oligomer Inhibitor for AD/RD PROJECT SUMMARY - SBIR/STTR Commercialization Readiness Pilot (CRP) Program (PAR-19-333) The long-term goal of this program is to develop a disease-modifying, small molecule drug for Alzheimer’s disease (AD) and related dementias (ADRD). There is a critical unmet need for a disease modifying drug for AD. Chronic treat ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Cartilage Regeneration with Tunable Inflammation Resistance

    SBC: Cytex Therapeutics, Inc.            Topic: R

    Abstract: Femoroacetabular impingement or FAI is a commonly diagnosed condition affecting a younger patient population than the general osteoarthritis (OA) population. Untreated, FAI invariably leads to OA and, ultimately, total hip arthroplasty (THA). The fact that most FAI diagnoses are made in patients under the age of 40, with many in their late teens and twenties, makes FAI all the more clini ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Improving Anticoagulation Monitoring in Pediatric Patients: Use of a Microfluidic Platform to Test Low Volume Blood Samples Obtained by Heel-Stick Collection

    SBC: Baebies, Inc.            Topic: NHLBI

    ABSTRACTImproving Anticoagulation Monitoring in Pediatric Patients: Use of a Microfluidic Platform to Test Low VolumeBlood Samples Obtained by Heel-Stick Collection Children treated for congenital heart defects or other disorders of hypercoagulation are prescribed unfractionated heparin (UFH) or low molecular weight heparin (LMWH) throughout surgical treatment; they may be prescribed heparin for u ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  4. KAPS Biotech: A novel biomarker to improve prostate cancer diagnosis

    SBC: Kaps Biotechnology LLC            Topic: 102

    Abstract Prostate cancer (CaP) is the most common non-skin cancer in men and third most common cause of cancer deaths in men. Black men experience a higher burden of incidence and mortality from CaP compared to White men. The Prostate-Specific Antigen (PSA) test, a commonly used biomarker for early diagnosis and management of CaP, cannot alone accurately predict the presence of CaP, its aggressive ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Development of EFTX-001 to target KRAS mutations in cancer

    SBC: Enfuego Therapeutics Inc.            Topic: 102

    Research Summary: The KRAS proto-oncogene is one of the most critical genes in cancer, yet it has also proven to be among the most elusive. Nearly all (98%) of KRAS missense mutations occur in codons 12 or 13, which leads to constitutive KRAS activation and promotion of numerous cancer hallmarks. Although kinase inhibitors have revolutionized treatment of some subsets of cancers driven by other mo ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a peptide-based diagnostic for amyotrophic lateral sclerosis

    SBC: AFFINERGY, LLC            Topic: NINDS

    SUMMARY/ABSTRACT Amyotrophic lateral sclerosis (i.e. ALS or Lou Gehrigandapos;s disease) is the most common adult-onset motor neuron disorder, with progressive weakness being the clinical hallmark. The average survival rate is 2-5 years post- diagnosis, but 10% of individuals survive ≥10 years, due to highly variable rates of progression. There is no cure for ALS, but there are treatments and in ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Inhaled Fasudil and DETA NONOate CAR-Targeted Liposomes for PAH

    SBC: VASCULAR BIOSCIENCES, INC.            Topic: NHLBI

    Pulmonary arterial hypertension (PAH) affects ~15-50 individuals per million and claims ≥20,000 lives annually in the United States. It affects every ethnic group, race, age and gender, and devastates high-risk patients afflicted with HIV, systemic sclerosis, and sickle cell disease. The disease affects more women than men; adult PAH patients do not live more than five years after the diagnosis. ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Immunoprofiling to develop a novel diagnostic array for cardiac sarcoidosis

    SBC: AFFINERGY, LLC            Topic: NHLBI

    SUMMARY/ABSTRACT Sarcoidosis is a disease of unknown etiology thought to arise after exposure to an antigenic stimulus and characterized by the formation of non-necrotizing granulomas containing immune cells. Systemic sarcoidosis affects over 25,000 people in the United States each year, with 150,000-200,000 total cases. Sarcoidosis granulomas can form in almost any organ of the body. Granulomas i ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Expanded Clinical Trial of Granulocyte Colony-Stimulating Factor (G-CSF) to Treat Hot Flush and Other Vasomotor Symptoms in Women with Naturally-Occurring and Surgically-Induced Menopause

    SBC: MENOGENIX, INC.            Topic: NIA

    One of the most common and distressing symptoms of menopause are hot flashes. Hot flashes and related symptoms represent a significant unmet, worldwide, healthcare need, not only in women after surgical or natural menopause, but also in breast and prostate cancer patients undergoing hormone suppression or ablation. Hot flashes occur in 65 – 90% of women undergoing natural menopause and approxima ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Low Temperature Sterilization Method for Flexible Endoscopes

    SBC: Brighton Development            Topic: NIAID

    ABSTRACT Healthcare-associated infections (HAI) are the single largest preventable medical cost in terms of both economic and humanitarian cost. The major significance of this problem is reflected in the $35-billion annual expenditure made for healthcare associated infections in the medical community. Due to the large number of procedures done each year, endoscopes are associated with more HAI out ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government